Chosa Oncology receives 94 Mount Sinai tumor samples for Platin-DRP validation study in advanced NSCLC chemo-immunotherapy

• Chosa Oncology received 94 tumor samples from Mount Sinai to validate its Platin-DRP test in advanced non-small cell lung cancer.
• The retrospective study assesses whether the test can flag patients most likely to benefit from platinum chemotherapy used with PD-1/PD-L1 immunotherapy.
• Earlier results were presented from the SPLENDOUR study, supporting the test’s ability to identify patients more likely to benefit from platinum treatment.
• First results from the Mount Sinai analysis will be presented in Q1 2027, a key step toward broader clinical adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 202610080433BITN____UKPR__SV_20261008-BIT-0656-0) on October 08, 2026, and is solely responsible for the information contained therein.